ClinicalTrials.gg
Not yet recruitingNCT07315984BioDigit HD-02Updated Oct 13, 2026

Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease

An observational study in Huntington Disease, sponsored by BioSensics. Not yet recruiting at 2 sites in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by BioSensics · Observational

How we know

Updated Oct 13, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.

Planned enrollment
32nd of 48
75 · median 131
Started
2027
the only one that year
Observational
48 of 138
14 open now
Primary completion
2028-08
later than 19 of 28 live
Registered
134th of 138
by date

Among the 138 studies in Huntington Disease with a site in United States, this one is the 32nd largest by planned enrollment of the 48 observational ones that give a count, is the only one that started in 2027, is one of 48 observational ones, reaches primary completion later than 19 of the 28 other live ones, and was the 134th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Huntington Disease with a site in United States, or all of them as a file.
02

Study summary

The objective of the study is to validate the use of wearable sensors and digital health technologies for monitoring disease activity in Huntington's Disease (HD). Healthy subjects, as well as subjects with documented diagnosis of HD will be screened and recruited at University of Rochester Medical Center and Vanderbilt University Medical Center to participate in this 12-month observational study. There will be a total of 5 visits every approximately 3 months.

In each study visit, participants will complete several Patient Reported Outcomes (PROs), Clinical Reported Outcomes, complete a series of Digital Assessments (Speech, Cognitive, Motor, and Finger Tapping). Participants will be provided with a pendant, wrist, and ankle sensors to monitor their daily physical activities for 7 days after each study visit. Participants will also be provided with a tablet to complete digital assessments (Speech, Cognitive, Motor, and Finger Tapping) on monthly basis at home.

Read the detailed description

HD is a devastating inherited neurological disorder that causes progressive nerve degeneration in the brain. HD is characterized by multifaceted symptomatology including motor, cognitive, and psychiatric symptoms, which begin insidiously and progress over many years. The principal means of measuring gross motor and speech impairment in HD is the Unified Huntington's Disease Rating Scale (UHDRS). Although valuable, the scale is subjective and categorical and requires significant training to administer correctly. Quantitative motor (Q-motor) tests have helped reduce subjectivity and improve sensitivity of motor assessments in HD. Q-Motor assessments have demonstrated utility in tracking longitudinal progression of motor impairment and as a supplemental measure in clinical trials. Likewise, force-sensitive insoles, video motion analysis systems, and pressure-sensitive walking mats have been utilized to objectively measure impaired gait in HD. However, these gait-measuring technologies and Q-Motor assessments must be administered in clinic by trained personnel. Similarly, the Montreal Cognitive assessment (MoCA) and Mini-mental State Examination, are often used to measure cognitive decline. However, these tests need to be administered by trained professionals and have limited ability to detect subtle changes in cognitive performance over time. Furthermore, measures are conducted infrequently, typically in a clinic setting, and may not be an accurate representation of an individual's true cognitive status.

There is currently no cure which can halt, slow or reverse the progression of the disease. The key challenge in development of new therapeutics in HD and other neurological disorders is that the current way of assessing the disease is largely subjective and requires in-person, in-clinic assessments. Digital measures, like the proposed solution can provide objective, real-world assessments of how individuals are functioning.

Wearable sensors and digital health technologies that can detect motor, speech, and cognitive abnormalities can provide insight into the phase of clinical disease onset. Given that gene positive premanifest stage of HD can take up to several years before the onset of symptomatic disease, the subtle changes in these biomarkers in the early stage of HD provide an opportune window to apply disease-modifying treatment that could potentially slow down or prevent the progression of the disease

Thus, a system that can objectively, sensitively, and frequently monitor multiple clinical domains (motor, speech and cognitive function) is necessary to understand the pattern of evolving motor, speech and cognitive abnormalities in individuals with prodromal HD, and for identification of endpoint measures for therapeutic trials.

This observational study will follow participants over 12 months. Healthy subjects, as well as subjects with documented diagnosis of HD will be screened and recruited at University of Rochester Medical Center and Vanderbilt University Medical Center. In addition to standard clinical assessments, the study will leverage BioDigit HD to collect wearable and digital health data from participants in at the study site and their home environments.

A key objective of the project is to measure changes in disease symptoms using patient reported outcomes (PROs), clinical reported outcomes, and digital measures in individuals with HD.

03

Conditions studied

  • Huntington Disease

Browse trials for

Keywords

  • huntington disease
  • wearable sensors
  • digital health
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults with clinical diagnosis of HD, and healthy age-matched controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 25-65 years
  • For HD participants: Genetically diagnosed with HD
  • Fluent in English (able to speak and read).
  • Ambulatory without the need for a walking aid.
  • Able to independently perform all study activities safely, as determined by the investigator.
  • Willing and able to provide and comply with all study procedures.

For control participants:

  • Male or female, aged 25-65 years
  • Clinically assessed to be in good health, with no evidence of neurological disorders that could cause involuntary movements or gait disturbances

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of juvenile-onset HD.
  • Individuals who are non-ambulatory.
  • Individuals with a neurological, medical, or psychiatric condition that, in the investigator's judgment, would interfere with safe participation in study activities.
  • (MoCA) score of 18 or lower
  • Pregnant individuals, due to potential changes in gait and physical activity during pregnancy.
  • Cannot be enrolled into a blinded intervention trial at baseline.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hungtinton's Disease

    Participants with clinical diagnosis of HD

  • Age-matched healthy adults

    Age-matched healthy adults. Clinically assessed to be in good health, with no evidence of neurological disorders that could cause involuntary movements or gait disturbances.

06

What researchers measure

Primary outcomes

  1. Change in daily walking duration during activities of daily living from baseline to 12 months as measured by the PAMSys pendant

    Daily walking duration (hours) will be measured by the PAMSys pendant. PAMSys is a FDA-listed Class II wearable device for measuring physical activity and posture during activities of daily living. PAMSys will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.

    Time frame: 12 months

  2. Change in daily number of sit to stand transitions (count) during activities of daily living from baseline to 12 months as measured by the PAMSys pendant.

    Daily number of sit to stand transitions will be measured by the PAMSys pendant. PAMSys is a FDA-listed Class II wearable device for measuring physical activity and posture during activities of daily living. PAMSys will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.

    Time frame: 12 months

Secondary outcomes

  1. Change in scores of Unified Huntington's Disease Rating Scale (UHDRS) from baseline to 12 months

    A clinical tool used to assess motor, cognitive, and behavioral symptoms in individuals with Huntington's disease (HD). There are 5 parts to UHDRS 1. Total Motor Score: Scores range from 0 to 124. Higher scores represent a worse outcome. 2. Total Functional Capacity: Scores range from 0 to 13. Lower scores represent a worse outcome. 3. Behavioral Assessment: Scores range from 0 to 88. Higher scores represent a worse outcome. 4. Cognitive Assessments: Inclues Stroop test, Verbal Fluency, and Symbol Digit Modalities Test. Lower scores represent a worse outcome.

    Time frame: 12 months

  2. Change in intelligibility when reading a standard Rainbow passage from baseline to 12 months as measured by BioDigit Speech

    Speech data will be collected from participants while reading a standard Rainbow passage on a monthly basis for 12 months. BioDigit Speech, and automatic speech analysis software, will be used to analyze the collected speech data to calculate intelligibility of speech during reading a standard Rainbow passage.

    Time frame: 12 months

  3. Change in walking speed during activities of daily living from baseline to 12 months as measured by the PAMSys Ankle sensor

    median, 90 percentile and 96 percentile stride velocity (m/s) will be measured by the PAMSys Ankle sensor. PAMSys Ankle sensor will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.

    Time frame: 12 months

  4. Change in cadence during activities of daily living from baseline to 12 months as measured by the PAMSys pendant

    Median, 90 percentile and 96 percentile cadence (steps/min) will be measured by the PAMSys pendant. PAMSys pendant will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.

    Time frame: 12 months

  5. Change in the Montreal Cognitive assessment (MoCA) score

    The MoCA will be assessed from participants during baseline, 3 month, 6 month, 9 month and 12 month visits.

    Time frame: 12 months

Other outcomes

  1. Change in tapping rate (number of taps per minute) from baseline to 12 months as measured by the BioDigit Clinic and BioDigit Home tablets

    Finger tapping test will be collected from participants on a monthly basis for 12 months.

    Time frame: 12 months

  2. Change in daily number of hand goal-directed movements during activities of daily living from baseline to 12 months as measured by the PAMSys ULM wrist sensor

    PAMSys ULM wrist sensor measures goal directed movements of the hand during activities of daily living. PAMSys ULM wrist sensors will be worn for 1 week after the baseline, 3 month, 6 month, 9 month, and 12 month visits.

    Time frame: 12 months

  3. Change in the Verbal Fluency test score

    Verbal fluency test data will be collected at baseline, 3 month, 6 month, 9 month and 12 month visits.

    Time frame: 12 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Aug 2028, 19 months later.

Of 34 observational studies under Huntington Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 34. This study's planned 19 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Jan 2027, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 5, 2026
StartEst.
Jan 31, 2027was Jan 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 31, 2026→Jan 31, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Jan 31, 2026→Jan 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07315984
Lead sponsor
BioSensics
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Jan 31, 2027 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Ana Enriquez
Contact
ana.enriquez@biosensics.com
888-589-6213 ext. 502

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion